Clinical trial · Interventional
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
Prospective, Multicenter, Parallel-Controlled Clinical Study on the Use of Huaier Granules for the Treatment of Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer Patients
NCT07358520CI-TRIAL-00101374not yet recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Proteinuria | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib and Bevacizumab | Drug | — | UNRESOLVED |
| Huaier Granule | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Huaier Granules
- description
- Take orally, 10g each time, three times a day. Participants in the experimental group should continue treatment for at least 24 weeks or until treatment failure, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; or until the investigator determines that there is no further benefit. For specific usage, refer to the drug instructions.
- interventionNames
- Drug: Huaier Granule
- type
- ACTIVE_COMPARATOR
- label
- Anlotinib and Bevacizumab
- description
- Administer according to clinical routine practice. Refer to the respective drug prescribing information for specific usage. Continue treatment until disease progression, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first.
- interventionNames
- Drug: Anlotinib and Bevacizumab
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years; * Histopathologically confirmed diagnosis of lung cancer; * Receiving Bevacizumab or Anlotinib treatment; * Positive urine protein detection, with 0.15g \< 24-hour urinary protein quantification \< 3.5g; * No treatment with Huaier Granules within one month prior to enrollment; * Expected survival time not less than 6 months; * Voluntary participation in this study and provision of signed informed consent. Exclusion Criteria: * Known allergy, contraindication, or caution to any component of Huaier Granules; * Inability to take oral medication; * Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (\>3 weeks), and Chinese patent medicines (as per respective drug prescribing information); * Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.; * Women who are pregnant, breastfeeding, or planning pregnancy; * Currently participating in other clinical trials investigating drugs for treating proteinuria; * Refusal to cooperate with follow-up; * Any other reasons deemed by the investigator as unsuitable for participation in this study.
References
Publications (0)
Data not yet available
No reference posted for this study.